PDS Biotechnology Corp PDSB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-25.61
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$34.5M | — | -$27.8M | $9.3M |
| 2024 | — | -$37.6M | — | -$35.1M | $19.0M |
| 2023 | — | -$42.9M | — | -$33.6M | $26.1M |
| 2022 | — | -$40.9M | — | — | $44.0M |
| 2021 | — | -$16.9M | — | — | $63.2M |
| 2020 | — | -$14.8M | — | — | $27.1M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -25.61 (distress)
- Working capital / assets 0.616
- Retained earnings / assets -7.103
- EBIT / assets -1.034
- Equity / liabilities 0.436
Source: SEC EDGAR filings · CIK 0001472091 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.